Thank you very much for the question, Madam Chair.
The original investment made in BioCanRx in 2015 was for $25 million. As I had mentioned, we were allowed to apply for reduced funding and we received another $15 million in 2020.
Currently, our spend is close to $30 million. We still have monies to put out in this upcoming year. With respect to attracting funding, the NCE program under which we were funded has an expectation of reaching a 1:1 funding match. Because of the space in which we operate and the ability to shepherd technologies and continue to add value as we bring them through the pre-clinical to clinical phase, we've been able to turn that $30-million spend into close to $96 million of leveraged funding going all the way back to 2015.
It's really because the type of engine we have built has been able to attract significant funding from a multitude of different sector partners.